Kenrick Ng· @Kenrickng1 · X·· 20 小时前评分70
正文 · 机器翻译
PEACE-1 长期更新（#ESMO2026，中位 FU 7.7 年）：
• Abiraterone + SOC：OS HR 0.75
• 三联方案（ADT+doc+abi）对比双联方案：mOS 6.2 vs 4.4 年，HR 0.68；8 年 OS 40% vs 27%
• 无论肿瘤负荷如何均可获益（交互作用 p=0.56）
• 高肿瘤负荷：8 年 OS 38% vs 20%
#ProstateCancer 1/2
8 浏览 · 0 赞 · 0 转发 · 1 回复
帖内回复
- Kenrick Ng@Kenrickng1
But 4 yrs on, maybe the debate isn't doublet vs triplet. It's what we do with poor responders. PSA >0.2 at ~6 months = major unmet need & opportunity. Good to see trials now focused here (PEACE-6 PR, TRIPLE-SWITCH, REINFORCE, EvoPAR-PR05), as Ursula Vogl discussed. #ESMO2026 2/2
来源：Kenrick Ng · x.com